Patrick Poisson - United Therapeutics Executive Operations
| UTHR Stock | USD 367.36 3.03 0.83% |
Executive
Patrick Poisson is Executive Operations of United Therapeutics
| Age | 56 |
| Address | 1000 Spring Street, Silver Spring, MD, United States, 20910 |
| Phone | 301 608 9292 |
| Web | https://www.unither.com |
United Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.1189 % which means that it generated a profit of $0.1189 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1881 %, meaning that it created $0.1881 on every $100 dollars invested by stockholders. United Therapeutics' management efficiency ratios could be used to measure how well United Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/22/2024, Return On Tangible Assets is likely to grow to 0.15. Also, Return On Capital Employed is likely to grow to 0.20. At this time, United Therapeutics' Return On Tangible Assets are relatively stable compared to the past year. As of 11/22/2024, Debt To Assets is likely to grow to 0.10, while Other Assets are likely to drop slightly above 284.7 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| James JD | Legend Biotech Corp | N/A | |
| Danielle Keatley | Ultragenyx | N/A | |
| Christopher MBA | MannKind Corp | 49 | |
| Janet Graesser | Vaxcyte | N/A | |
| Pamela Murphy | Incyte | 73 | |
| Christine Lindenboom | Alnylam Pharmaceuticals | 43 | |
| MBA MD | Replimune Group | 58 | |
| Paula Swain | Incyte | 66 | |
| Ariel Hurley | Blueprint Medicines Corp | 50 | |
| Saraswathy Nochur | Alnylam Pharmaceuticals | 63 | |
| JD Esq | Apellis Pharmaceuticals | 51 | |
| Indrani JD | Alnylam Pharmaceuticals | 51 | |
| Matthew Moore | Ventyx Biosciences | 51 | |
| Matthew PharmD | MannKind Corp | 54 | |
| Paul MBA | Vaxcyte | 63 | |
| DO Sr | Larimar Therapeutics | 63 | |
| Andrew Schwendenman | Replimune Group | 48 | |
| Caroline MD | Apellis Pharmaceuticals | 57 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Tolga MBA | Alnylam Pharmaceuticals | 51 | |
| Aaron Olsen | Ultragenyx | N/A | |
Management Performance
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.12 |
United Therapeutics Leadership Team
Elected by the shareholders, the United Therapeutics' board of directors comprises two types of representatives: United Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of United. The board's role is to monitor United Therapeutics' management team and ensure that shareholders' interests are well served. United Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, United Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Edgemond, CFO and Treasurer | ||
| Holly Hobson, Associate Resources | ||
| JD MBA, Chairman Founder | ||
| Gil Golden, Senior Officer | ||
| Dewey CFA, Head Relations | ||
| Kevin Gray, Senior Logistics | ||
| Michael Benkowitz, President COO | ||
| Patrick Poisson, Executive Operations | ||
| Paul JD, General VP | ||
| Leigh Peterson, Executive Xenotransplantation |
United Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is United Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.19 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.40 % | ||||
| Operating Margin | 0.55 % | ||||
| Current Valuation | 13.34 B | ||||
| Shares Outstanding | 44.64 M | ||||
| Shares Owned By Insiders | 1.84 % | ||||
| Shares Owned By Institutions | 98.16 % | ||||
| Number Of Shares Shorted | 2.3 M | ||||
| Price To Earning | 23.49 X |
Pair Trading with United Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against United Stock
| 0.66 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.65 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.63 | MTEM | Molecular Templates | PairCorr |
| 0.62 | NKTX | Nkarta Inc | PairCorr |
| 0.57 | TPST | Tempest Therapeutics | PairCorr |
The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.
The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.